GlassScriptPhysician profile
Ehab Abdelgyed
NPI 1902467897
$4,150.79
in general payments reported to CMS, 2019-2025
23 companies · $2,037 in 2025
The $2,037 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $630 · 2024: $1,483 · 2025: $2,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,204 · Travel and Lodging: $897 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,204.13 |
| Travel and Lodging | $896.71 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,349.57 | 2024-2025 | Minimed 780g |
| Dexcom, INC. | $377.28 | 2024-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor |
| Sanofi-Aventis U.S. LLC | $371.06 | 2024 | |
| Novo Nordisk INC | $346.86 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.04 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $216.49 | 2023-2024 | |
| Horizon Therapeutics Plc | $206.06 | 2023 | Tepezza |
| Amgen INC. | $162.26 | 2024-2025 | Evenity, Prolia, Prolia |
| Corcept Therapeutics | $143.21 | 2023-2024 | Korlym |
| Insulet Corporation | $124.71 | 2024 | Omnipod |
| Radius Health, INC. | $115.11 | 2024-2025 | Tymlos |
| Tandem Diabetes Care, INC. | $102.70 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Kvk-Tech, INC. | $66.14 | 2025 | |
| Lilly USA, LLC | $56.13 | 2024-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $49.95 | 2025 | Freestyle Insulinx |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $45.60 | 2024-2025 | |
| Alvogen INC | $23.50 | 2024 | Teriparatide |
| Averitas Pharma INC. | $21.52 | 2025 | Qutenza |
| Eisai INC. | $20.51 | 2025 | |
| Xeris Pharmaceuticals, INC. | $19.67 | 2024 | Recorlev |
| Kyowa Kirin, INC. | $18.94 | 2024 | |
| Beta Bionics, INC. | $18.05 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Rhythm Pharmaceuticals, INC. | $17.43 | 2024 | Imcivree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ehab Abdelgyed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.